v3.25.1
CONDENSED CONSOLIDATED STATEMENTS OF SHAREHOLDERS' EQUITY (Unaudited) - USD ($)
$ in Thousands
Total
Common Shares
Additional Paid in Capital
Accumulated Other Comprehensive Loss
Accumulated Deficit
Beginning balance (in shares) at Oct. 31, 2023   23,197,976      
Beginning balance at Oct. 31, 2023 $ 72,486 $ 259,373 $ 13,717 $ (1,016) $ (199,588)
Share-based compensation expense 291   291    
Issuance of warrants in connection with Amended Term Loan expense 319   319    
Net loss (10,711)       (10,711)
Ending balance (in shares) at Jan. 31, 2024   23,197,976      
Ending balance at Jan. 31, 2024 62,385 $ 259,373 14,327 (1,016) (210,299)
Beginning balance (in shares) at Oct. 31, 2023   23,197,976      
Beginning balance at Oct. 31, 2023 72,486 $ 259,373 13,717 (1,016) (199,588)
Net loss (25,695)        
Ending balance (in shares) at Apr. 30, 2024   44,158,587      
Ending balance at Apr. 30, 2024 242,966 $ 453,405 15,860 (1,016) (225,283)
Beginning balance (in shares) at Jan. 31, 2024   23,197,976      
Beginning balance at Jan. 31, 2024 62,385 $ 259,373 14,327 (1,016) (210,299)
Exercise of stock options (in shares)   56,974      
Exercise of stock options 51 $ 207 (156)    
Share-based compensation expense 1,917   1,917    
Issuance of common shares in connection with PIPE Financing, net of issuance costs (in shares)   20,000,000      
Issuance of common shares in connection with PIPE Financing, net of issuance costs 187,614 $ 187,614      
Issuance of common shares upon exercise of warrants (in shares)   520,282      
Issuance of common shares upon exercise of warrants 5,983 $ 6,114 (131)    
Issuance of common shares upon cashless exercise of warrants (in shares)   383,355      
Issuance of common shares upon cashless exercise of warrants   $ 97 (97)    
Net loss (14,984)       (14,984)
Ending balance (in shares) at Apr. 30, 2024   44,158,587      
Ending balance at Apr. 30, 2024 242,966 $ 453,405 15,860 (1,016) (225,283)
Beginning balance (in shares) at Oct. 31, 2024   50,976,676      
Beginning balance at Oct. 31, 2024 272,612 $ 509,811 18,950 (1,419) (254,730)
Exercise of stock options (in shares)   884      
Exercise of stock options 1 $ 1      
Share-based compensation expense 1,809   1,809    
Other comprehensive income (loss) 144     144  
Net loss (24,616)       (24,616)
Ending balance (in shares) at Jan. 31, 2025   50,977,560      
Ending balance at Jan. 31, 2025 249,950 $ 509,812 20,759 (1,275) (279,346)
Beginning balance (in shares) at Oct. 31, 2024   50,976,676      
Beginning balance at Oct. 31, 2024 $ 272,612 $ 509,811 18,950 (1,419) (254,730)
Exercise of stock options (in shares) 94,175        
Net loss $ (50,431)        
Ending balance (in shares) at Apr. 30, 2025   51,070,851      
Ending balance at Apr. 30, 2025 227,291 $ 510,121 23,300 (969) (305,161)
Beginning balance (in shares) at Jan. 31, 2025   50,977,560      
Beginning balance at Jan. 31, 2025 249,950 $ 509,812 20,759 (1,275) (279,346)
Exercise of stock options (in shares)   93,291      
Exercise of stock options 200 $ 309 (109)    
Share-based compensation expense 2,650        
Other comprehensive income (loss) 306     306  
Net loss (25,815)       (25,815)
Ending balance (in shares) at Apr. 30, 2025   51,070,851      
Ending balance at Apr. 30, 2025 $ 227,291 $ 510,121 $ 23,300 $ (969) $ (305,161)